argenx SE reported $110.75M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
AstraZeneca USD 2.47B 232M Jun/2025
Galapagos EUR 4.71M 9.02M Jun/2025
Genmab DKK 57M 15M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
GRIFOLS EUR 1.15B 56.19M Jun/2025
Hikma Pharmaceutical USD 895M 82M Dec/2024
Qiagen NV USD 199.25M 24.48M Jun/2025
UCB EUR 901M 50M Dec/2024